Silence Therapeutics Plc ADR (SLN) Stock Price, Quote & News

Company Profile

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elev...

Industry: Biotechnology

Sector: Healthcare

Phone: 44 20 3457 6900

Website: www.silence-therapeutics.com

Address:

12 Hammersmith Grove, London, United Kingdom

SadyK189 Jun. 29 at 8:05 PM

Here is my Amazing daily "Stocktwits" report 2/2: $SKYQ $SLN $BLZE $WSHP SKYQ Price 2.28. My post was "Good close of daily candle. Key support zone at 1.6 - 1.78. Next key level to test 2.8 - 3.05." It made a nice move to 4.13 today SLN Price 9.25. My post was "SLN is trending nicely on daily chart. 7.6 - 8.1 is acting as key support zone. Next key level to test 9.95 - 10.45." It hit our desired zone, went till 10.99 today BLZE My post was "Initially alerted at 12.43. Still looking good on daily chart with updated support zone at 11.30- 11.80. Next key level to test 16.25 - 16.75." It went till 15.65 today WSHP Price 7.76. My post last night "Looking good on 4hours chart. 6.1 - 6.55 is acting as key support zone. Next key level to test 8.8 - 9.45." It hit our desired zone, went till 10.92 today

0 · Reply

SadyK189 Jun. 29 at 6:09 PM

$SLN Price 9.25. My post was "SLN is trending nicely on daily chart. 7.6 - 8.1 is acting as key support zone. Next key level to test 9.95 - 10.45." It hit our desired zone, went till 10.86 today

0 · Reply

Aawilliam2003 Jun. 26 at 2:47 AM

$SLN not sure why this is getting bid up. They’ve been very clear that a phase 3 will be required after the phase 2. Makes this 3+ years from approval assuming all goes well with trial data

1 · Reply

prismmarketview Jun. 25 at 4:15 PM

PRISM Mid-Day Movers: NextGen Tech & AI and Psychedelics are Today’s Leaders. BlackBerry Limited (NYSE: $BB ) is putting in a strong session today, with the stock up about 20% to 10.37 from a prior close of 8.62. Cybin Inc., doing business as Helus Pharma (NASDAQ: $HELP ), is putting in a strong move today, with the stock up about 19% to 6.06 from a prior close of 5.09. Other Notable Movers: Silence Therapeutics ( $SLN) up 15% Personalis, Inc. ( $PSNL) up 10% Sangamo Therapeutics ( $SGMO) down -53% #PRISMMarketView #PrismMidDayMovers #EmergingGrowth #MicroCapStocks #SmallCapMomentum https://prismmarketview.com/prism-mid-day-movers-nextgen-tech-ai-and-psychedelics-are-todays-leaders/

0 · Reply

StockMan3517 Jun. 25 at 2:43 PM

$SLS BO soon hopefully so I can load $GUTS and $SLN

1 · Reply

laaarsas Jun. 25 at 1:15 PM

$SLN We continue up today? How high before data?

0 · Reply

GSP Jun. 25 at 11:44 AM

$BTQ $ICCM $SKYQ $BCRX $SLN

0 · Reply

Merlintrader Jun. 25 at 9:43 AM

$PLSM $ICCM $SLN: Remote Care, Cryoablation and siRNA Catalysts Move Back Into Focus https://www.merlintrader.com/back-in-focus-jun25-biotech/

0 · Reply

StockScanners Jun. 25 at 12:56 AM

$SLN keep watch if this holds above 8.88

0 · Reply

SadyK189 Jun. 25 at 12:23 AM

Top Stocks to watch tomorrow 1 / 2: $AZI $SCAG $ICCM $SKYQ $SLN AZI: Good close of 4hours candle. Key support zone at 1.6 - 1.75. Next key level to test 2.75 - 2.95. Currently at 2.29 SCAG: Looking good on 4hours chart. Key support zone at 0.51 - 0.54. Next key level to test 0.79 - 0.84. Currently at 0.65 ICCM: Initially alerted at 6.08. Currently at 9.35. Good close of daily candle with updated support zone at 7.30 - 7.65. Next key level to test 10.45 - 10.70. SKYQ: Good close of daily candle. Key support zone at 1.6 - 1.78. Next key level to test 2.8 - 3.05. Currently at 2.28 SLN is trending nicely on daily chart. 7.6 - 8.1 is acting as key support zone. Next key level to test 9.95 - 10.45. Currently at 9.25

1 · Reply

Cantor starts ‘materially undervalued’ Silence Therapeutics at Overweight

2026-06-24T10:10:31.000Z - 10 days ago

Silence Therapeutics initiated with an Overweight at Cantor Fitzgerald

Jun 23, 2026, 7:00 AM EDT - 11 days ago

Silence Therapeutics Slides: Corporate presentation

2026-06-11T11:36:45.000Z - 23 days ago

Silence Therapeutics highlights follow-up data on divesiran at EHA 2026

Jun 11, 2026, 7:30 AM EDT - 23 days ago

Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera

Jun 3, 2026, 4:55 PM EDT - 4 weeks ago

Silence Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

May 27, 2026, 8:00 AM EDT - 5 weeks ago

Silence Therapeutics to Participate in Jefferies Global Healthcare Conference

May 19, 2026, 2:00 PM EDT - 6 weeks ago

Silence Therapeutics Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

2026-05-18T20:16:33.000Z - 6 weeks ago

Silence Therapeutics files $300M ordinary shares offering

May 18, 2026, 8:00 AM EDT - 6 weeks ago

Silence Therapeutics Registration statement: Registration filing

May 12, 2026, 8:00 AM EDT - 7 weeks ago

Silence Therapeutics to Participate in H.C. Wainwright BioConnect Investor Conference

2026-05-08T08:30:11.000Z - 2 months ago

Silence Therapeutics price target lowered to $27 from $35 at Chardan

2026-05-07T13:21:52.000Z - 2 months ago

Silence Therapeutics reports Q1 EPS (11c) vs. (20c) last year

May 7, 2026, 8:00 AM EDT - 2 months ago

Silence Therapeutics Highlights Recent Business Achievements and Reports First Quarter 2026 Financial Results

May 7, 2026, 8:00 AM EDT - 2 months ago

Silence Therapeutics Earnings release: Q1 2026

May 7, 2026, 8:00 AM EDT - 2 months ago

Silence Therapeutics Quarterly report: Q1 2026

May 6, 2026, 7:00 AM EDT - 2 months ago

Silence Therapeutics Slides: Corporate presentation

Apr 29, 2026, 8:00 AM EDT - 2 months ago

Silence Therapeutics Proxy statement: Proxy filing

Mar 5, 2026, 7:30 AM EST - 4 months ago

Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 5, 2026, 7:30 AM EST - 4 months ago

Silence Therapeutics Annual report: Q4 2025

Mar 5, 2026, 7:30 AM EST - 4 months ago

Silence Therapeutics Earnings release: Q4 2025

Mar 5, 2026, 7:30 AM EST - 4 months ago

Silence Therapeutics Annual report: Q4 2025

2025-12-15T13:20:39.000Z - 7 months ago

Silence Therapeutics CEO Craig Tooman to end employment

Dec 15, 2025, 8:13 AM EST - 7 months ago

Silence Therapeutics Announces Leadership Changes

Nov 19, 2025, 8:00 AM EST - 8 months ago

Silence Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 12, 2025, 8:00 AM EST - 8 months ago

Silence Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare Conference

2025-11-06T14:06:04.000Z - 8 months ago

Silence Therapeutics reports Q3 EPS (15c), consensus (21c)

Nov 6, 2025, 7:30 AM EST - 8 months ago

Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 6, 2025, 7:30 AM EST - 8 months ago

Silence Therapeutics Quarterly report: Q3 2025

Nov 6, 2025, 7:30 AM EST - 8 months ago

Silence Therapeutics Earnings release: Q3 2025

2025-10-23T11:41:01.000Z - 9 months ago

Silence Therapeutics completes patient enrollment in SANRECO

Oct 23, 2025, 7:30 AM EDT - 9 months ago

Silence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera (PV)

Sep 9, 2025, 5:35 PM EDT - 10 months ago

Silence Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 2, 2025, 8:00 AM EDT - 10 months ago

Silence Therapeutics to Participate in September Investor Conferences

2025-08-07T12:37:16.000Z - 11 months ago

Silence Therapeutics reports Q2 EPS (19c), consensus (21c)

Aug 7, 2025, 7:30 AM EDT - 11 months ago

Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Aug 7, 2025, 7:30 AM EDT - 11 months ago

Silence Therapeutics Quarterly report: Q2 2025

Aug 7, 2025, 7:30 AM EDT - 11 months ago

Silence Therapeutics Earnings release: Q2 2025

2025-06-12T20:05:13.000Z - 1 year ago

Silence Therapeutics presents additional Phase 1 data highlighting Divesiran

Jun 12, 2025, 4:01 PM EDT - 1 year ago

Silence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia Vera

May 16, 2025, 8:00 AM EDT - 1 year ago

Silence Therapeutics Proxy statement: Proxy Filing

2025-05-08T12:35:24.000Z - 1 year ago

Silence Therapeutics reports Q1 EPS (20c), consensus (41c)

May 8, 2025, 8:00 AM EDT - 1 year ago

Silence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 8, 2025, 7:00 AM EDT - 1 year ago

Silence Therapeutics Quarterly report: Q1 2025

May 8, 2025, 7:00 AM EDT - 1 year ago

Silence Therapeutics Earnings release: Q1 2025

May 6, 2025, 8:00 AM EDT - 1 year ago

Silence Therapeutics Proxy statement: Proxy Filing

May 6, 2025, 7:45 AM EDT - 1 year ago

Silence Therapeutics Welcomes Tim McInerney to Board of Directors

Mar 12, 2025, 1:00 PM EDT - 1 year ago

Silence Therapeutics Transcript: Leerink’s Global Healthcare Conference 2025

Mar 5, 2025, 8:00 AM EST - 1 year ago

Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference

2025-02-27T20:50:10.000Z - 1 year ago

Silence Therapeutics price target lowered to $30 from $31 at Jefferies

2025-02-27T13:01:36.000Z - 1 year ago

Silence Therapeutics reports FY25 net loss 33c vs. 49c loss last year

2025-02-27T13:01:08.000Z - 1 year ago

Silence Therapeutics extends projected cash runway into 2027

Feb 27, 2025, 8:00 AM EST - 1 year ago

Silence Therapeutics Earnings Call Transcript: Q4 2024

Feb 27, 2025, 8:00 AM EST - 1 year ago

Silence Therapeutics Annual report: Q4 2024

Feb 27, 2025, 8:00 AM EST - 1 year ago

Silence Therapeutics Earnings release: Q4 2024

Feb 27, 2025, 8:00 AM EST - 1 year ago

Silence Therapeutics Slides: Q4 2024

Feb 27, 2025, 7:30 AM EST - 1 year ago

Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Feb 13, 2025, 8:00 AM EST - 1 year ago

Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025

2025-02-10T21:21:22.000Z - 1 year ago

Goldman starts Silence Therapeutics at Sell on ‘undifferentiated’ data

2025-02-10T21:15:39.000Z - 1 year ago

Silence Therapeutics initiated with a Sell at Goldman Sachs

Dec 9, 2024, 7:30 AM EST - 1 year ago

Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting

Dec 4, 2024, 10:00 AM EST - 1 year ago

Silence Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 26, 2024, 8:00 AM EST - 1 year ago

Silence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare Conference

Nov 25, 2024, 2:00 AM EST - 1 year ago

Silence Therapeutics Earnings release: Q3 2024

Nov 20, 2024, 9:00 AM EST - 1 year ago

Silence Therapeutics Transcript: Jefferies London Healthcare Conference 2024

Nov 18, 2024, 2:30 PM EST - 1 year ago

Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting

Nov 14, 2024, 8:00 AM EST - 1 year ago

Silence Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 13, 2024, 8:00 AM EST - 1 year ago

Silence Therapeutics to Participate in Fireside Chat at the Jefferies London Healthcare Conference

Sep 30, 2024, 9:00 AM EDT - 1 year ago

Silence Therapeutics Transcript: Chardan Genetic Medicines Conference

Sep 17, 2024, 10:20 AM EDT - 1 year ago

Silence Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 10, 2024, 11:30 AM EDT - 1 year ago

Silence Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 5, 2024, 5:35 PM EDT - 1 year ago

Silence Therapeutics Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 27, 2024, 8:00 AM EDT - 2 years ago

Silence Therapeutics to Webcast Presentations at Upcoming September Investor Conferences

Aug 15, 2024, 8:00 AM EDT - 2 years ago

Silence Therapeutics Earnings release: Q2 2024

Aug 15, 2024, 7:30 AM EDT - 2 years ago

Silence Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Jun 27, 2024, 8:30 AM EDT - 2 years ago

Silence Therapeutics Transcript: Study Result

Jun 27, 2024, 8:30 AM EDT - 2 years ago

Silence Therapeutics Press release: Study Result

Jun 27, 2024, 8:30 AM EDT - 2 years ago

Silence Therapeutics Slides: Study Result

Jun 27, 2024, 7:30 AM EDT - 2 years ago

Silence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients

Jun 24, 2024, 8:30 AM EDT - 2 years ago

Silence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma Collaboration

Jun 20, 2024, 7:30 AM EDT - 2 years ago

Silence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a)

May 30, 2024, 8:30 AM EDT - 2 years ago

Silence Therapeutics to Present at Jefferies Global Healthcare Conference

May 16, 2024, 8:30 AM EDT - 2 years ago

Silence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline Progress

May 16, 2024, 7:00 AM EDT - 2 years ago

Silence Therapeutics Earnings release: Q1 2024

May 7, 2024, 8:00 AM EDT - 2 years ago

Silence Therapeutics Registration statement: Registration Filing

Apr 30, 2024, 8:30 AM EDT - 2 years ago

Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference

Apr 29, 2024, 8:30 AM EDT - 2 years ago

Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors

Apr 8, 2024, 11:48 AM EDT - 2 years ago

Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)

Mar 13, 2024, 8:00 AM EDT - 2 years ago

Silence Therapeutics Earnings Call Transcript: Q4 2023

Mar 13, 2024, 8:00 AM EDT - 2 years ago

Silence Therapeutics Annual report: Q4 2023

Mar 13, 2024, 8:00 AM EDT - 2 years ago

Silence Therapeutics Earnings release: Q4 2023

Mar 13, 2024, 8:00 AM EDT - 2 years ago

Silence Therapeutics Slides: Q4 2023

Mar 13, 2024, 7:05 AM EDT - 2 years ago

Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights

Mar 13, 2024, 7:00 AM EDT - 2 years ago

Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)

Feb 28, 2024, 8:00 AM EST - 2 years ago

Silence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024

Feb 23, 2024, 8:00 AM EST - 2 years ago

Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial

Feb 5, 2024, 8:00 AM EST - 2 years ago

Silence Therapeutics Announces Oversubscribed $120 Million Private Placement

Jan 31, 2024, 7:00 AM EST - 2 years ago

Silence Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Dec 1, 2023, 7:00 AM EST - 2 years ago

Silence Therapeutics Strengthens Executive Leadership Team with Key Appointments

Nov 14, 2023, 7:00 AM EST - 2 years ago

Silence Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results

Nov 14, 2023, 7:00 AM EST - 2 years ago

Silence Therapeutics Earnings release: Q3 2023

Nov 13, 2023, 12:00 PM EST - 2 years ago

Silence Therapeutics Transcript: Study Update

Nov 8, 2023, 7:00 AM EST - 2 years ago

Silence Therapeutics to Present at Jefferies London Healthcare Conference

Nov 1, 2023, 7:00 AM EDT - 2 years ago

Silence Therapeutics Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular Disease

Sep 26, 2023, 7:00 AM EDT - 3 years ago

Silence Therapeutics to Participate in Fireside Chat at Chardan's 7th Annual Genetic Medicines Conference

Sep 11, 2023, 9:20 AM EDT - 3 years ago

Silence Therapeutics Transcript: Morgan Stanley 21st Annual Global Healthcare Conference 2023

Aug 16, 2023, 7:00 AM EDT - 3 years ago

Silence Therapeutics Reports Second Quarter 2023 Results

Aug 16, 2023, 7:00 AM EDT - 3 years ago

Silence Therapeutics Earnings release: Q2 2023

Jul 11, 2023, 7:00 AM EDT - 3 years ago

Silence Therapeutics Achieves $4 Million in Research Milestone Payments from Hansoh Pharma Collaboration

May 31, 2023, 7:00 AM EDT - 3 years ago

Silence Therapeutics to Present at the Jefferies Healthcare Conference

May 16, 2023, 4:00 PM EDT - 3 years ago

Silence Therapeutics Reports First Quarter 2023 Results

May 16, 2023, 7:00 AM EDT - 3 years ago

Silence Therapeutics Earnings release: Q1 2023

May 4, 2023, 7:00 AM EDT - 3 years ago

Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration

May 1, 2023, 7:00 AM EDT - 3 years ago

Silence Therapeutics Completes Enrollment in Phase 2 Study of Zerlasiran (SLN360) in Subjects with Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events

Apr 25, 2023, 7:00 AM EDT - 3 years ago

Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect Investor Conference

SadyK189 Jun. 29 at 8:05 PM

0 · Reply

SadyK189 Jun. 29 at 6:09 PM

$SLN Price 9.25. My post was "SLN is trending nicely on daily chart. 7.6 - 8.1 is acting as key support zone. Next key level to test 9.95 - 10.45." It hit our desired zone, went till 10.86 today

0 · Reply

Aawilliam2003 Jun. 26 at 2:47 AM

$SLN not sure why this is getting bid up. They’ve been very clear that a phase 3 will be required after the phase 2. Makes this 3+ years from approval assuming all goes well with trial data

1 · Reply

prismmarketview Jun. 25 at 4:15 PM

0 · Reply

StockMan3517 Jun. 25 at 2:43 PM

$SLS BO soon hopefully so I can load $GUTS and $SLN

1 · Reply

laaarsas Jun. 25 at 1:15 PM

$SLN We continue up today? How high before data?

0 · Reply

GSP Jun. 25 at 11:44 AM

$BTQ $ICCM $SKYQ $BCRX $SLN

0 · Reply

Merlintrader Jun. 25 at 9:43 AM

$PLSM $ICCM $SLN: Remote Care, Cryoablation and siRNA Catalysts Move Back Into Focus https://www.merlintrader.com/back-in-focus-jun25-biotech/

0 · Reply

StockScanners Jun. 25 at 12:56 AM

$SLN keep watch if this holds above 8.88

0 · Reply

SadyK189 Jun. 25 at 12:23 AM

1 · Reply

GSP Jun. 24 at 9:10 PM

Your Day Trading Watch List for June 25th in About 2 Minutes: $BTQ $ICCM $SKYQ $BCRX $SLN .

1 · Reply

JesterOfWallSt Jun. 24 at 7:04 PM

$NWGL Reload Time 💣 $SLN $SCAG $PLSM

0 · Reply

ShadowNick Jun. 24 at 6:29 PM

$SLN on watch as well

0 · Reply

laaarsas Jun. 24 at 3:57 PM

$SLN Why up today?

1 · Reply

notreload_ai Jun. 24 at 2:41 PM

Cantor Fitzgerald sees $SLN as "significantly undervalued." The firm initiated Overweight coverage citing strong divesiran Phase 2 potential and 160%+ upside. https://notreload.xyz/xy/cantor-fitzgerald-initiates-overweight-on-silence-therapeutics/

0 · Reply

focafoca99 Jun. 23 at 8:49 PM

$SLN issued an updated corporate presentation reflecting recent business updates.

0 · Reply

nnnuuu Jun. 22 at 2:31 PM

$SLN we gonna get some NVS or IONS news soon, surely

0 · Reply

laaarsas Jun. 11 at 2:37 PM

$SLN Oh wow. Really that big pop just in today’s PR? Hopefully it signals nice rerating if study results are good.

0 · Reply

focafoca99 Jun. 11 at 11:48 AM

$SLN released follow-up Phase 1 data on divesiran for polycythemia vera from the SANRECO study at EHA 2026.

2 · Reply

laaarsas Jun. 5 at 11:59 AM

$SLN Anyone cares to make a geuss what share price will be if ph2 shows efficacy on par with rusfertide? Is that a clear positive or do we need to see more?

0 · Reply

laaarsas Jun. 4 at 7:07 PM

$SLN Low activity here. Readout is probably still some months away.

0 · Reply

laaarsas Jun. 1 at 8:45 PM

$SLN Please help me understand

0 · Reply

Market Cap	490.77M
Revenue (ttm)	560,000.00
Net Income (ttm)	-88.61M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-15,823.21%
Debt to Equity Ratio	0.00

Volume	696,700
Avg Vol	381,828
Day's Range	N/A - N/A
Shares Out	47.24M
Stochastic %K	84%
Beta	1.38
Analysts	Strong Sell
Price Target	$31.20